Presentation is loading. Please wait.

Presentation is loading. Please wait.

Evidence-Informed Best Practices Rheumatoid Arthritis Osteoarthritis Dr. Diane Lacaille.

Similar presentations


Presentation on theme: "Evidence-Informed Best Practices Rheumatoid Arthritis Osteoarthritis Dr. Diane Lacaille."— Presentation transcript:

1 Evidence-Informed Best Practices Rheumatoid Arthritis Osteoarthritis Dr. Diane Lacaille

2 2 Describe the rationale for key recommendations for best practice care for Rheumatoid Arthritis and Osteoarthritis according to the BC Guidelines. Objective

3 3 Rationale for recommendations in guidelines  Rheumatoid Arthritis  Early diagnosis and early treatment with DMARDs  Prevention of joint damage  Management of co-morbidities  Monitoring of disease activity  Osteoarthritis  Reduction of pain  Improvement of function  Optimization of conservative care  Appropriate and timely referral for surgical intervention

4 4

5 5 EARLY Treatment of RA with DMARDs EARLY DIAGNOSIS AND TREATMENT OF RA AGGRESSIVE USE OF DMARDS ALTERS THE COURSE OF RA REMISSION IS THE NEW TARGET OF RA TREATMENT LONG TERM USE OF DMARDS YES, DMARDS ARE SAFE WHEN MONITORED REGULARLY This is the new standard of care. EARLYEARLY

6 6 If not controlled, RA inflammation leads to:  joint damage and joint deformities  progressive loss of physical function  work disability (32-50% after 10 years of RA)  premature mortality, mainly from cardiovascular disease (50% increase in risk of death from CVD) All these outcomes are preventable. RA is Not a Benign Disease

7 7 Persistent Joint Swelling Leads to Joint Damage & Deformities =>

8 8 Early Diagnosis & Treatment of RA Early diagnosis Recognizing signs of inflammation – clues pointing to RA  Early morning stiffness > 30 minutes  Worse pain in the morning and post immobility  Swelling of small joints  Pain or tenderness on squeezing the MTP s, MCP s or wrists  Symmetrical involvement  Systemic symptoms, such as fatigue Ruling out other diagnosis  Septic arthritis, especially if monoarthritis  Crystal arthritis, such as gout or pseudogout  Joint aspiration for acute monoarthritis to R/O infection or when crystal arthritis is suspected  Transient inflammatory arthritis (viral) < 6 weeks  Other inflammatory arthritis, also Rx with DMARDs EARLYEARLY

9 9 Early treatment of RA Capture the window of opportunity  Early treatment with DMARD s alters the disease course.  Joint damage occurs early (within months) and is irreversible.  RA is more responsive to treatment early on.  Early treatment increases the chances of remission. New onset RA requires urgent care  DMARD s should be started within 2 months of symptoms.  Referral to a rheumatologist for new onset RA should be seen within 4 weeks. State ‘new onset of RA ’ on referral.  Rheumatologists prefer early referrals. EARLYEARLY Early Diagnosis & Treatment of RA

10 10 Aggressive use of DMARD s Alters the course of RA What are DMARDs?  Disease Modifying Anti-Rheumatic Drugs  They improve symptoms and prevent joint damage.  Methotrexate, Sulfasalazine, Hydroxychloroquine, Gold, Cyclosporine, Leflunomide and biologic agents. Think RA, think DMARDs  All RA patients with active inflammation should be on a DMARD. NSAIDs and prednisone are not enough  NSAIDs improve symptoms but fail to prevent joint damage.  Prednisone should not be used alone because of long term toxicities EARLYEARLY

11 11 Role of steroids in RA  Minimize steroids dose and duration, because of long term risks, esp. cardiovascular diseases  Oral steroids do have a role:  Small doses (< 10 mg daily), over short periods  Bridging therapy, while waiting for DMARDs  Early on at time of RA onset, but avoid prior to rheumatologist referral for diagnosis bcse masks signs.  To control flare-ups  Intramuscular (40 mg depomedrol) and intra- articular are good alternatives to oral.  If steroids are needed to control disease, then DMARDs need to be adjusted 11

12 12  DMARDs alter the course of RA by: Preventing joint damage and deformities Reducing physical and work disability Preventing premature mortality  Aggressive use of DMARDs means: Starting DMARDs early Using DMARDs continuously, often in combination Evaluating response every 1 to 3 months Modifying DMARD therapy until the target is reached Aiming to eradicate inflammation Aggressive Use of DMARD s Alters the Course of RA EARLYEARLY

13 13 The goal of RA treatment is no longer to simply control symptoms, but to eradicate inflammation. The target of DMARD therapy is no signs of active inflammation i.e., No swollen joints Normal ESR or CRP Little to no radiographic progression Although remission is the target, minimal disease activity may be an acceptable alternative, when remission is not possible, especially in established long-standing disease, or when co-morbidities or other patient factors limit DMARD options. EARLYEARLY Remission is the new target of RA treatment

14 14  DMARDs should be used continuously, throughout the disease.  When sustained remission is achieved, DMARDs may be slowly decreased to find a lower dose that maintains remission.  DMARD discontinuation is not recommended because of high risk of flare off DMARDs.  All RA requires DMARD, the earlier the better, but even late RA requires DMARDs to reduce further damage. Long-term use of DMARD s EARLYEARLY

15 15 RisksBenefits reduce mortality reduce disability prevent deformity improve symptoms cost toxicity Benefits of early DMARD s outweigh their risks Yes DMARDs are safe when monitored regularly EARLYEARLY

16 16

17 17  Family physicians play a critical role in early diagnosis and treatment of RA.  DMARDs should be prescribed in all RA patients and should be started early. EARLY is the new standard of care

18 18 NSAIDS DMARDs Treatment of RA the standard of care has changed

19 19 Management of Established RA Objective: Suppress inflammation, prevent joint damage TaskFamily DoctorRheumatologist MonitorQ 2-6 monthsQ 6-12 months Assess disease activity (Joint Count + Blood Work) Review Meds, S/E Adherence/ Dosage Refer to PT/OT Review/adjust meds Rating of Disease Activity for decision- making Assess Joint DamagePain Relief Refer PT/OT, surgery same Review for Co- morbidities Screen and Treat

20 20 Consider chronic disease implications Comorbidities  Dealing with Chronic Pain  Psychosocial Issues  Increased infection risk  Immunizations  Osteoporosis  Cardiovascular Disease  Smoking Cessation  Weight Management

21 Osteoarthritis

22 22 Features suggestive of OA:  Absence of inflammatory features: morning stiffness < 30 min; gelling < 5 min; minimal swelling & heat; no redness.  Pain worse with activity, better with rest  Advanced OA => constant pain including at rest  Absence of systemic symptoms  Gradual onset  History of prior injury (e.g. knee), prior deformity / malalignement  Joint distribution: hips, knees, C & L spine, hands: DIP, PIP, 1 st CMC, 1st MTP.  Bony enlargement, crepitus, malalignement  If joint swelling, synovial fluid non-inflammatory, no crystals. Osteoarthritis (OA)

23 23 Joint Distribution Black= joints most commonly affected Grey= joints often affected White= joints usually not affected

24 24  Septic arthritis (acute monoarthritis requires joint aspiration)  Crystal arthritis: gout, pseudogout (CPPD) (joint aspiration)  Inflammatory arthritis: esp. psoriatic arthritis  Non-articular : e.g. bursitis (trochanteric, pes anserine), tendonitis (shoulder, elbow)  Bone pain (multiple myeloma, metastasis)  Soft tissue pain syndromes  Referred pain Other Diagnoses to Exclude

25 25  X Rays › Provide clinical information › Can be normal in early OA › Often don’t correlate with degree of pain › Knee Xrays must be ordered weight bearing (PA, lat, skyline) › Hip (OA hip series: incl. lateral view and upper 1/3 femur)  Absence of inflammatory markers (CBC, CRP normal)  Labs can be useful to rule out other conditions (e.g. thyroid disease) or to assess for comorbidities prior to Rx (e.g. Cr, LFT) Investigations

26 26  Severity of pain (with activity, at rest, interferes with sleep)  Impact on function (ADLs, IADLs)  Impact on participation (work, family obligations, social activities, leisure)  Impact on independence  Psychosocial issues (pain amplification, coping strategies, depression, adherence to treatment, social support) Management - Considerations

27 27 Patient Education (OA and RA)  Guidelines  Patient Support  Family Support  Community Support  Patient Self Management (coping with pain and other arthritis symptoms, stress, lifestyle changes e.g. exercise).  Arthritis Self Management Program (ASMP) and CDSMP.

28 28  Patient education  Self-management  Weight management – support, dietician  Exercise (ROM, strengthening, aerobic)  Physiotherapy: prescribe specific therapeutic exercise program  Walking aids  Occupational therapy: Orthotics, footwear, braces, splints, ADL aids, ergonomic modifications at work Management – Non pharmacological

29 29  Acetaminophen: › regular schedule vs. prn › up to 4 gm/day, less if liver disease  NSAIDs: › Gastroprotection if high GI risk › Consider cardiovascular risk factors › Topical NSAIDs  Glucosamine and chondroitin sulfate: › Not recommended, insufficient evidence of efficacy  Intra-articular steroids  Hyaluronic acid – limited benefit, can cause inflammatory reaction Management - Pharmacological

30 30

31 31  Differentiating inflammatory from non-inflammatory arthritis  Importance of early diagnosis and DMARD treatment in RA  Monitoring of disease activity to achieve treatment target  Goal of preventing joint damage, consequences of inflammation  Management of pain, improvement of function in OA  Weight management, exercise and rehab in OA  Multidisciplinary care of arthritis  Appropriate and timely referral for surgery  Management of co-morbidities, esp. cardiovascular diseases  Need for shared approach to care  Importance of patient education and self-management Summary


Download ppt "Evidence-Informed Best Practices Rheumatoid Arthritis Osteoarthritis Dr. Diane Lacaille."

Similar presentations


Ads by Google